Pipeline
Pipeline
Leveraging over 30 years of experience and expertise compiled in medicinal chemistry, LCB uses its proprietary drug-like compounds, namely, "building blocks" to accelerate drug discovery research and are assembling a robust pipeline of innovative small molecule programs in collaboration with global partners.
Our Pipeline
Small molecule
Program
Indication
Partner
Stage
Discovery
Preclinical
Phase1
Phase2
Phase3
Notes
Antibiotics
Antibiotics, which first appeared on the market in 1941, were actively developed and released until the 1960s, but the development of antibiotics rapidly declined due to the absence of new antibiotics and limitations in technology. In addition, it is a development field in which unmet needs in the global pharmaceutical market are rapidly increasing with the advent of super bacteria that are resistant to existing antibiotics.
LegoChem Bio is developing antibiotics that can treat Gram-negative bacteria and Gram-positive bacteria that do not have adequate treatment due to serious resistance problems.
LegoChem Bio is developing antibiotics that can treat Gram-negative bacteria and Gram-positive bacteria that do not have adequate treatment due to serious resistance problems.
Delpazolid
Gram-positive
-DS-TB, MDR-TB
-MRSA, VRE,
-S. pneumoniae
-MRSA, VRE,
-S. pneumoniae
Partner
임상2상
- Orphan Drug
- QIDP
- Fast Track
- QIDP
- Fast Track
Partner
임상1상
- L/O for China (‘16.12)
Anti-fibrotics
We are developing antifibrotic drugs that improve the fibrosis effect and minimize toxicity by discovering and introducing novel substances.
LCB17-0877
(ATX Inhibitor)
IPF, fibrotic diseases
Partner
임상1상
- L/O for global (Profit Sharing)
LCB17A
Next-Gen ATXi
NASH, Oncology
Partner
Discovery
- Improved efficacy and safety
Anti-coagulants
The largest medical unmet need in the field of anticoagulants used in the prevention and treatment of coronary artery disease (angina pectoris, myocardial infarction) and stroke is internal bleeding. LegoChem Bio is developing FXa inhibitors that minimize bleeding side effects using LegoChemistry, a technology based on our synthetic drug development.
LCB02-0133
Nokxaban,FXa Inhibitor
Partner
Preclinical
L/O for global (Profit Sharing)
Partner
임상1상
Sub L/O for China (‘18.01)
Immuno Oncology
Partner
Discovery
- I/O Targeted
-Combi with ADC
-Payloads for ADC
-Combi with ADC
-Payloads for ADC